10-Q: Tenon Medical Reports Q2 Revenue Drop, Going Concern Warning

Tenon Medical, Inc. reported a significant decline in Q2 revenue and gross profit, alongside a reduced net loss, but disclosed substantial doubt about its ability to continue as a going concern and identified material internal control weaknesses.

Summary

• Net loss for the three months ended June 30, 2025, was $(2,769) thousand, a reduction from $(3,826) thousand for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $(6,385) thousand, a reduction from $(7,402) thousand for the same period in 2024.
• Revenue for the three months ended June 30, 2025, decreased by 37% to $564 thousand from $901 thousand in Q2 2024, primarily due to fewer surgical procedures.
• Revenue for the six months ended June 30, 2025, decreased by 20% to $1,290 thousand from $1,620 thousand in the same period in 2024.
• Gross profit for the three months ended June 30, 2025, decreased by 48% to $245 thousand, with the gross profit percentage falling from 52% to 43%.
• Gross profit for the six months ended June 30, 2025, decreased by 40% to $568 thousand, with the gross profit percentage falling from 58% to 44%.
• Total operating expenses decreased by 29% to $3,102 thousand for Q2 2025 and by 15% to $7,102 thousand for the six months ended June 30, 2025.
• Cash and cash equivalents increased to $7,846 thousand as of June 30, 2025, from $6,535 thousand at December 31, 2024, primarily due to financing activities.
• The accumulated deficit reached $75.1 million as of June 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• The company completed two strategic acquisitions in August 2025: SImmetry Acquisition and SIMPL Acquisition, expanding its sacropelvic fixation and SI joint implant technology.
• A material weakness in internal controls was identified due to insufficient segregation of duties.

Sentiment

Score: 3

Explanation: While the net loss decreased and cash reserves increased due to financing, the significant decline in revenue and gross profit, coupled with the explicit 'going concern' warning and identified material weakness in internal controls, indicates a very challenging financial position and high operational risk. The strategic acquisitions are positive but come at a time of significant financial vulnerability.

Positives

• Net loss decreased for both the three months (from $(3,826) thousand to $(2,769) thousand) and six months (from $(7,402) thousand to $(6,385) thousand) ended June 30, 2025, compared to the prior year periods.
• Total operating expenses decreased significantly across research and development, sales and marketing, and general and administrative categories for both the three-month and six-month periods.
• Cash and cash equivalents increased to $7,846 thousand as of June 30, 2025, from $6,535 thousand at December 31, 2024, bolstered by recent financing activities.
• Successfully raised capital through warrant exercises and securities purchase agreements in March 2025, generating net proceeds of $2,735 thousand, $1,234 thousand, and $2,290 thousand respectively.
• Completed strategic acquisitions of SImmetry and SIMPL Medical assets in August 2025, which are expected to expand the product portfolio in sacropelvic fixation and SI joint implant technology.
• Hired Wyatt Geist as Chief Innovation Officer and Nate Grawey as Chief Commercial Officer in connection with the SImmetry Acquisition, strengthening the management team.

Negatives

• Revenue decreased by 37% to $564 thousand for the three months ended June 30, 2025, and by 20% to $1,290 thousand for the six months, primarily due to a decrease in surgical procedures.
• Gross profit decreased by 48% to $245 thousand for the three months and by 40% to $568 thousand for the six months ended June 30, 2025.
• Gross profit percentage declined from 52% to 43% for the three months and from 58% to 44% for the six months.
• The accumulated deficit increased to $75.1 million as of June 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• A material weakness in internal controls was identified due to insufficient segregation of duties, impacting the effectiveness of disclosure controls and procedures.

Risks

• Substantial doubt exists about the ability to continue as a going concern for at least twelve months from the filing date due to historical losses and negative cash flows from operations.
• Inability to raise necessary additional capital through public or private equity offerings, debt financings, or collaborations on acceptable terms or at all.
• Potential dilution of existing stockholders' ownership interest if additional capital is raised through equity offerings.
• Risk of being subject to covenants limiting or restricting specific actions if additional capital is raised through debt financing.
• The company may have to delay, reduce the scope of, or suspend sales and marketing efforts, research and development activities, or other operations if unable to obtain adequate financing.
• Uncertainty of future revenues from The Catamaran System.
• Changes in business strategy, regulatory developments, or research and development spending plans could consume available capital resources more rapidly than expected.
• A material weakness in internal controls due to insufficient segregation of duties could adversely affect the ability to record, process, summarize, and report financial information reliably.
• Operating in a highly competitive medical devices industry.
• Ability to respond and adapt to changes in technology and customer behavior.
• Ability to protect intellectual property and to develop, maintain, and enhance a strong brand.

Future Outlook

The company expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as it continues its product development programs and the commercialization of The Catamaran System. Existing cash and cash equivalents are not believed to be sufficient to meet obligations for at least the next twelve months, necessitating additional capital raises through public or private equity offerings, debt financings, and collaborations.

Management Comments

• Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System.
• Based on the Company's expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of June 30, 2025 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these financial statements.
• Management believes that there is substantial doubt in our ability to continue as a going concern for the next twelve months from the issuance of these condensed financial statements.
• Our Chief Executive Officer and President and Chief Financial Officer concluded that our disclosure controls and procedures are not effective at the reasonable assurance level.
• Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties. Therefore, it is difficult to effectively segregate accounting duties which comprises a material weakness in internal controls.

Industry Context

Operating in the highly competitive medical devices industry, Tenon Medical focuses on sacroiliac joint (SI Joint) disorders with its Catamaran SI Joint Fusion System. The recent acquisitions of SImmetry and SIMPL Medical assets indicate a strategic move to expand its portfolio in sacropelvic fixation and posterior SI joint implant technology. This expansion aims to address the significant, underserved market for chronic lower back pain associated with SI Joint dysfunction, positioning the company to offer more comprehensive solutions and potentially increase its market share.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks.
• The company highlights that its initial clinical results for The Catamaran System implant are promoting fusion across the joint, as evidenced by computerized tomography (CT) scans, which is considered the gold standard by the clinical community. However, no comparative data against competitor devices or industry-wide success rates are provided within the filing.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face potential significant dilution from ongoing and future equity capital raises, as well as uncertainty regarding the company's ability to continue as a going concern.
• Employees, particularly those in R&D and commercial roles, may see increased activity and potential for new hires following the recent acquisitions and continued product development efforts.
• Customers (clinicians) may benefit from an expanded product portfolio in sacropelvic fixation and SI joint implant technology due to the SImmetry and SIMPL acquisitions.
• Creditors face increased risk due to the company's stated substantial doubt about its ability to continue as a going concern and its reliance on future capital raises.

Next Steps

• Obtain stockholder approval for the exercisability of Series C-1 and Series C-2 Warrants no later than 165 days after March 11, 2025.
• Continue efforts to raise additional capital through equity offerings, debt financings, and collaborations to fund operations for the next twelve months.
• Improve The Catamaran System and develop new products, including undergoing clinical activities for regulatory clearances of future products.
• Increase the capacity of qualified financial personnel to address the identified material weakness in internal controls and ensure adequate segregation of duties.
• Determine the fair value of acquired tangible and intangible assets and liabilities for the SImmetry and SIMPL acquisitions, and disclose supplemental pro-forma information in a Current Report on Form 8-K.

Key Dates

Recommendation

The significant decline in revenue and gross profit, coupled with the explicit 'going concern' warning and identified material weakness in internal controls, indicates severe financial distress and high operational risk. While the company has raised capital and made strategic acquisitions, these actions appear to be reactive to a deteriorating financial position rather than indicative of strong underlying performance. The ongoing need for continuous capital raises and the uncertainty of future revenues make this a high-risk investment with a strong likelihood of further share price depreciation and potential for significant capital loss.

Keywords

Tenon Medical, TNON, medical device, sacroiliac joint, SI joint fusion, Catamaran System, SImmetry Acquisition, SIMPL Acquisition, Q2 2025 earnings, financial results, going concern, internal controls, equity offering, warrants, orthopedics, back pain treatment